PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 10, 2026Asian Pacific Journal of Cancer Prevention0 citationsOpen Access

Standardizing Cost-Effectiveness Evidence for Cancer Prevention: A Case Study Analysis of HPV Vaccination

AJAlireza Mosavi JarrahiSRSoheila RajaieSASamad Azari

Key Points

  • The central aim is to standardize cost-effectiveness evidence for HPV vaccination to guide investment decisions.
  • Analysis of cost-effectiveness evidence for HPV vaccination.
  • Assessment of investment opportunities in low- and middle-income countries (LMICs).
  • Evaluation of metrics used by international funders and policymakers.
  • Cost-effectiveness evidence supports accelerated HPV vaccination efforts.
  • Health equity is promoted through standardized economic evaluations.
  • Investment priorities are clearer for LMICs where returns are maximally beneficial.

Abstract

The CER is a simple yet powerful tool that transforms incomparable data into a standardized metric. For international funders like Gavi and national policymakers, it provides robust evidence to prioritize investments in LMICs, where the return on investment is highest. By reframing the economic question from "can we afford it?" to "how can we afford not to?", the CER promotes health equity and strengthens the case for accelerating global HPV vaccination efforts.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Jarrahi et al. (2026) studied this question.

synapsesocial.com/papers/69af959570916d39fea4d537https://doi.org/10.31557/apjcp.2026.27.3.789
Ask AI
Helpful
Bookmark
Share
View Full Paper